CXCL10 and metabolic dysfunction-associated steatohepatitis: In a recent study, diosmetin significantly ameliorated inflammatory responses via STAT1/CXCL10 signaling in a high-fat-diet-induced nonalcoholic steatohepatitis (NASH) mouse model and palmitic-acid-stimulated HepG2 cells, indicating diosmetin as a potential biomolecule in suppressing inflammation in NASH conditions [135].